個(gè)性化醫(yī)學(xué)(ISSN 1741-0541)將最近基因組學(xué)、遺傳學(xué)和蛋白質(zhì)組學(xué)的進(jìn)展轉(zhuǎn)化為臨床應(yīng)用。該雜志為所有參與者提供了一個(gè)綜合論壇，包括學(xué)術(shù)和臨床研究人員、制藥公司、監(jiān)管機(jī)構(gòu)、醫(yī)療管理組織、患者組織和醫(yī)療行業(yè)的其他組織。個(gè)性化醫(yī)療通過(guò)提供一個(gè)專家評(píng)論和分析的平臺(tái)，幫助這些團(tuán)體塑造醫(yī)學(xué)的未來(lái)。該雜志涉及個(gè)性化醫(yī)療的科學(xué)、商業(yè)和政策問(wèn)題，包括新聞和觀點(diǎn)，對(duì)新生物標(biāo)志物的最新認(rèn)識(shí)，簡(jiǎn)明的評(píng)論和分析，會(huì)議巡回報(bào)告和完整的綜述文章。提交給個(gè)性化醫(yī)療的文章必須經(jīng)過(guò)嚴(yán)格的同行審查。討論的主題包括:分子診斷的進(jìn)展;生物芯片/微陣列技術(shù);針對(duì)特定遺傳和免疫靶點(diǎn)的生物療法或疫苗方法;個(gè)性化醫(yī)療的成本效益問(wèn)題;個(gè)性化醫(yī)療倫理;個(gè)性化醫(yī)療對(duì)醫(yī)療保健和制藥行業(yè)的影響基于藥物基因組學(xué)、藥物基因?qū)W和藥物蛋白質(zhì)組學(xué)的個(gè)性化藥物發(fā)展的最新概念的影響將遺傳分析納入臨床試驗(yàn)方法;診斷與治療相結(jié)合;藥物不良反應(yīng)及安全性預(yù)測(cè)治療監(jiān)測(cè)。

Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape the future of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in Personalized Medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles. Articles submitted to Personalized Medicine are subject to rigorous peer review. Topics addressed include: Advances in molecular diagnostics; Biochip/microarray technologies; Biological therapies or vaccine approaches at specific genetic and immunologic targets; Cost-benefit issues for personalized medicine; Ethics in personalized medicine; Impact of personalized medicine on healthcare and the pharmaceutical industry; Impact of the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics and pharmacoproteomics; Incorporation of genetic analysis in clinical trials methodology; Integration of diagnosis with therapy; Prediction of adverse reactions of drugs and drug safety; Treatment monitoring.